Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at email@example.com
Nurses Can Build Strategies to Facilitate More Meaningful Discussions With Patients and CaregiversApril 28th 2022
Oncology nurses are in less control of their communication environment compared with other health care providers; however, certain strategies can help them communicate effectively with their patients.
Creating a Safe Space Is the First Step in Initiating Sexual Health Conversations With Patients With CancerApril 28th 2022
The most important thing that an oncology nurse can do to help a patient navigate their sexual health is repeatedly offer them permission to have conversations surrounding their health.
Bioimpedance Spectroscopy May Play a Large Role in Proactively Preventing Chronic LymphedemaApril 25th 2022
Patients who underwent prospective surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.
Adjuvant Capecitabine Continues as Mainstay in Biliary Tract Cancer, But More Research Is Needed in Neoadjuvant SettingApril 19th 2022
A long-term analysis of the phase 3 BILCAP study highlighted modest benefit for patients with resected biliary tract cancer who received capecitabine following surgery.
FDA Follow-Up: Utilizing Pembrolizumab for MSI-H/dMMR Advanced Endometrial CarcinomaApril 8th 2022
Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Uncracking the Code on Oncology Nurse Satisfaction During a Magnet® JourneyMarch 28th 2022
Two healthcare professionals with Cancer Treatment Centers of America® (CTCA) Phoenix, a comprehensive care and research center recently recognized with Magnet® distinction, discuss the importance of transparency in nursing satisfaction and engagement.
FDA Follow-Up: Utilizing Relatlimab/Nivolumab in Clinical Practice for Metastatic MelanomaMarch 25th 2022
Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.
Adjuvant Pembrolizumab Reduces Recurrence Risk in Resectable NSCLCMarch 25th 2022
Findings from the KEYNOTE-091 trial showed that patients with non–small cell lung cancer who were treated with pembrolizumab following complete resection and chemotherapy had a 24% decreased risk of recurrence compared with a control arm.
FDA Follow-Up: Utilizing Olaparib in Clinical Practice for BRCA+ High Risk Early Breast CancerMarch 24th 2022
Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.
FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate CancerMarch 24th 2022
Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy.
Cancer Treatment–Related AEs Are More Prevalent in Women Vs MenMarch 22nd 2022
New research shows that women are at an increased risk of developing an adverse event following cancer therapy compared with their male counterparts. This risk is particularly elevated among patients receiving immunotherapy.
Investigators Set to Assess Novel Immunotherapy/Chemo Combo in Advanced Ovarian CancerMarch 21st 2022
The ongoing FLORA-5 trial will assess whether the addition of oregovomab to a standard chemotherapy regimen will improve progression-free and overall survival in patients with advanced epithelial ovarian cancer.